Le Lézard
Classified in: Health
Subjects: RCL, CFG

Advisory - Certain Lots of Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled due to potential presence of particulate matter


OTTAWA, March 31, 2020 /CNW/ -

Summary

Product: Taro-Zoledronic acid injection 5mg/100mL, used for osteoporosis and Paget's disease

Issue: Taro Pharmaceuticals Inc. is recalling five lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100), due to the potential presence of particulate matter.

What to do: Check the lot number on your product or contact your pharmacist to determine whether any of your products are subject to this recall. If you have a recalled product do not take the medication and, contact your healthcare provider to obtain a replacement product. If you have taken a recalled product and have any concerns about your health, contact your healthcare provider.

Issue
Health Canada is advising Canadians that Taro Pharmaceuticals Inc. is recalling five lots of Taro-Zoledronic acid injection 5mg/100mL (DIN 02415100) because of the potential presence of particulate matter in the drug. Zoledronic acid is used to treat and prevent osteoporosis, as well as to treat Paget's disease (i.e., a condition that causes bone deformities).

If injected, the presence of particles could cause   inflammation or irritation of veins that could cause blockage of blood vessels.  In the most serious of cases it could cause lung damage, serious allergic reactions or formation of blood clots.

All lots of the drug distributed by Taro Pharmaceuticals Inc. between August 1, 2018, and December 24, 2019, are affected by the recall. Health Canada is monitoring the recall, and should the Department become aware of additional safety information, it will take appropriate action and inform Canadians as necessary.

Who is affected
Patients who are taking, or who have taken, Taro-Zoledronic acid injection 5mg/100mL, or patients who have obtained this product from a pharmacy.

Affected products

 

Company

Product
Name/Active
Pharmaceutical
Ingredient (API)

DIN

Strength

Lot

Expiry

Taro
Pharmaceutical
Inc.

Taro-Zoledronic acid
injection

 

02415100

5mg/100mL

JKT1520A

April 2020

JKT1580A 

May 2020

JKT1581A  

May 2020

JKT1642A

May 2020

JKT1643A

May 2020

 

What consumers should do

What Health Canada is doing
Health Canada is monitoring the recall and verifying that the company has effectively addressed the issue. Should additional safety concerns be identified, Health Canada will take appropriate action and inform Canadians as necessary.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 08:30
SimBioSys, a pioneering TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and computational modeling to redefine precision medicine for cancer, today announced a strategic collaboration with Magic Leap to...

at 08:30
Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegratm CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly...

at 08:30
BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Saga University located in Saga, Japan and known for its commitment to educating and training researchers and professionals in the medical and healthcare...

at 08:30
Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer,...

at 08:25
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million. The financing was led by RA...

at 08:25
Masimo today announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety. Kiani's speech, "Empowering Patient Safety Through AI," will discuss how artificial...



News published on and distributed by: